Boai NKY Medical Holdings Ltd.

Boai NKY Medical Holdings Ltd. (NKY Group) is a China-based, Shenzhen Stock Exchange-listed company (stock code: 300109) established in 2003, with roots tracing back to a 1987 state-owned chemical plant. The company operates through two primary business segments: fine chemicals and precision medicine. Its fine chemical division focuses on the research, development, and production of polyvinylpyrrolidone (PVP) and PVM/MA (Orarez) polymer series. NKY is recognized as the largest Chinese manufacturer of PVP and the third largest globally, utilizing advanced production facilities in Jiaozuo and Shanghai to produce materials used across the pharmaceutical, personal care, food and beverage, and new energy industries.

The company’s precision medicine segment includes the manufacturing of in vitro diagnostic products and investments in innovative oncology pharmaceuticals. NKY’s business model emphasizes technological innovation, international development, and rigorous quality standards, being the first Chinese manufacturer to achieve EXCiPACT GMP certification for its pharmaceutical excipients. With a global distribution network spanning over 50 countries, the company serves multinational partners by providing specialized polymer solutions and diagnostic tools. NKY is committed to sustainable development, evidenced by its membership in the United Nations Global Compact and ongoing efforts in environmental responsibility, including the conversion to green production processes and resource recycling.